RxDoctor Payments Data

Kevin Kimata, MD

Neurology · Honolulu, HINPI 1598763781

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 1,133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Among neurology clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$23,658in general payments, 2019–2025

Across 1,133 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • AstraZeneca$1K
  • Amgen$937
  • Neurocrine Biosciences, Inc.$818
  • plus $12K from 53 others

What the payments were for

  • Speaking & faculty fees$1180%
  • Food & beverage$23,38299%
  • Education$1591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)178$3,731
UCB, Inc.106$2,746
Teva Pharmaceuticals USA, Inc.110$1,998
AstraZeneca39$1,001
Amgen(2 entities)37$937
Neurocrine Biosciences, Inc.29$818
Biogen35$799
Sunovion Pharmaceuticals Inc.70$795
Pfizer62$783
Lundbeck LLC32$749
Eisai Inc.33$726
Harmony Biosciences LLC22$616
Jazz Pharmaceuticals Inc.20$522
Argenx US, Inc.20$468
SK Life Science, Inc.25$456
Neurelis, Inc.26$455
Tanabe Pharma America, Inc.22$450
Amneal Pharmaceuticals LLC23$440
Novartis22$417
Acorda Therapeutics, Inc17$404
Acadia Pharmaceuticals Inc18$367
CSL Behring14$276
Biohaven Pharmaceutical Holding Company Ltd.19$265
Kyowa Kirin, Inc.14$263
EMD Serono, Inc.11$255
Otsuka America Pharmaceutical, Inc.11$254
Takeda Pharmaceuticals U.S.A., Inc.9$253
Upsher-smith Laboratories LLC12$231
TG Therapeutics, Inc.7$172
Alnylam Pharmaceuticals Inc.6$151
Bristol Myers Squibb7$138
Grifols USA, LLC6$130
Adamas Pharmaceuticals, Inc.6$128
Sanofi5$125
Vanda Pharmaceuticals Inc.3$105
Lilly USA, LLC4$100
Biohaven Pharmaceuticals, Inc.4$86
Avanir Pharmaceuticals, Inc.4$82
Livanova USA, Inc.4$79
Catalyst Pharmaceuticals, Inc.3$74
Kowa Pharmaceuticals America, Inc.4$71
Genentech, Inc.3$67
Akcea Therapeutics, Inc.2$56
Supernus Pharmaceuticals, Inc.3$55
Axsome Therapeutics, Inc.2$54
Merz Pharmaceuticals, LLC2$52
Arbor Pharmaceuticals, Inc.3$50
Mallinckrodt Hospital Products Inc.2$46
Merz North America, Inc.2$45
Insightec,inc2$44
Sarepta Therapeutics, Inc.2$43
Medtronic2$43
Amarin Pharma, Inc.2$37
Genentech USA, Inc.2$37
Otsuka Pharmaceutical Development & Commercialization, Inc.1$28
Amylyx Pharmaceuticals, Inc.1$24
ITF Therapeutics LLC1$22
Greenwich Biosciences, Inc.1$19
Cala Health, Inc.1$18

How this compares

$23,658 in reported general payments places this provider in the 90th percentile of 54 neurology providers in Hawaii.

See all neurology providers in Hawaii

Medicare billing

Part B allowed, 2024
$183,954
Medicare patients
385
Services billed
10,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UltomirisRavulizumab-Cwvz12$482,177
Kesimpta PenOfatumumab13$131,801
BotoxOnabotulinumtoxina43$59,319
Aimovig AutoinjectorErenumab-Aooe23$27,302
Rasagiline Mesylate47$9,189
Lacosamide36$6,352
Carbidopa-Levodopa ErCarbidopa/Levodopa34$6,005
Eletriptan HbrEletriptan Hydrobromide14$3,806
Carbidopa11$3,652
Duloxetine Hcl23$3,089
Carbidopa-LevodopaCarbidopa/Levodopa111$2,699
Pramipexole DihydrochloridePramipexole Di-Hcl63$2,572
Gabapentin47$2,373
Pyridostigmine Bromide19$2,251
Donepezil Hcl91$1,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaUltomiris$1,001$482,17712 claims
AbbVieBotox$3,731$59,31943 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$440$2,25119 claims
Upsher-smith Laboratories LLCTopiramate$231$41731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 54 neurology providers in Hawaii.

Other neurology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →